@article {7806,
	title = {International prognostic scoring system for Waldenstr{\"o}m macroglobulinemia},
	journal = {Blood},
	volume = {113},
	year = {2009},
	note = {Cited By :148Export Date: 21 February 2017},
	month = {2009},
	pages = {4163 - 4170},
	abstract = {Recently, many new drugs have been developed for the treatment of Waldenstr{\"o}m macroglobulinemia (WM). To optimize the treatment according to the prognosis and to facilitate the comparison of trials, we developed an International Prognostic Scoring System for WM in a series of 587 patients with clearly defined criteria for diagnosis and for initiation of treatment. The median survival after treatment initiation was 87 months. Five adverse covariates were identified: advanced age (\&gt;65 years), hemoglobin less than or equal to 11.5 g/dL, platelet count less than or equal to 100 {\texttimes} 10 9/L, β2-microglobulin more than 3 mg/L, and serum monoclonal protein concentration more than 7.0 g/dL. Low-risk patients (27\%) presented with no or 1 of the adverse characteristics and advanced age, intermediate-risk patients (38\%) with 2 adverse characteristics or only advanced age, and high-risk patients (35\%) with more than 2 adverse characteristics. Five-year survival rates were 87\%, 68\%, and 36\%, respectively (P \&lt; .001). The ISSWM retained its prognostic significance in subgroups defined by age, treatment with alkylating agent, and purine analog. Thus, the ISSWM may provide a means to design risk-adapted studies. However, independent validation and new biologic markers may enhance its significance. {\textcopyright} 2009 by The American Society of Hematology.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-66149155411\&doi=10.1182\%2fblood-2008-08-174961\&partnerID=40\&md5=29dc8e05f9b47681d5c8ff2d0262edaa},
	author = {Morel, P. and Duhamel, A. and Gobbi, P. and Dimopoulos, M.A. and Dhodapkar, M.V. and McCoy, J. and Crowley, J. and Ocio, E.M. and Garcia-Sanz, R. and Treon, S.P. and Leblond, V. and Kyle, R.A. and Barlogie, B. and Merlini, G.}
}
